About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Daily Archives: February 12, 2020
FDA Takes A Number of Actions to Enhance the Market for Biosimilars – A Process Not an Event
There is a policy interest in driving the biosimilar market. Among other reasons, increasing the number of generic drugs and biosimilars on the market addresses another policy priority – having an impact on the high cost of medicine. The approval … Continue reading
Posted in Biologics, FDA Policy
Comments Off on FDA Takes A Number of Actions to Enhance the Market for Biosimilars – A Process Not an Event